Date: 2016-08-25
Type of information: Distribution agreement
Compound: Sandovac®, Fluad®
Company: Valneva (France- Austria) Seqirus (UK)
Therapeutic area: Infectious diseases
Type agreement: distribution marketing
Action mechanism: vaccine
Disease: influenza
Details: * On August 25, 2016, Valneva announced the signing of an agreement with Seqirus, the second largest flu company in the world, for the marketing & distribution of Seqirus’ seasonal flu vaccines Sandovac® and Fluad®
in the Austrian market. Seqirus is the global company created in July 2015 from the combined strength and expertise of bioCSL Inc. and the influenza vaccine business formerly owned by Novartis.
Under the terms of the agreement, Valneva will start distributing the Sandovac® and Fluad® vaccines to the Austrian market at the beginning of the 2016-2017 flu season.
The Sandovac® vaccine is licensed in Europe for the prevention of influenza infections in individuals 6 months of age and older while the Fluad® vaccine is approved for active immunization against influenza disease for use in persons 65 years of age and older in more than 30 countries.
Valneva, which established its own global commercial network in 2015, expects to sign additional agreements for the marketing and distribution of other third-party vaccines.
Financial terms:
Latest news:
